ABSTRACT. Recent innovations in the genomic understanding of medulloblastomas have provided new ways to explore this highly invasive malignant brain cancer arising from the cerebellum. Among the four different medulloblastoma subgroups described to date, the sonic hedgehog (SHH) genetic pathway is the pathway activated in the tumorigenesis of medulloblastoma. SHH-related medulloblastomas are usually of nodular/desmoplastic histology and frequently occur in children under the age of three, an age group highly susceptible to the acute and long-term effects of treatment. Several new drugs aimed at SHH modulation are currently under development. This review focuses on the role of arsenic trioxide, a drug well established in clinical practice and probably an under-explored agent in medulloblastoma management, in the SHH pathway.
INTRODUCTION
Tumors of the central nervous system (CNS) are amongst the most common pediatric neoplasias, representing about 20 to 23% of all childhood cancers. In some study series, CNS tumors have shown the highest mortality rates, only lower than those for lymphohematopoietic diseases (Rickert and Paulus, 2001; Kool et al., 2012) .
Medulloblastomas (MB) are the most common malignant brain tumors in children, corresponding to approximately 20% of all brain tumors in children younger than 15 years and accounting for significant morbidity-mortality rates (Patel et al., 2014) . In more than 80% of the cases, they occur as midline tumors primarily originating in the cerebellar vermis. Metastases may be present at diagnosis or occur later (de Bont et al., 2008; Korshunov et al., 2010; Wells et al., 2010) . The incidence of MB peaks among 6-to 8-year-old children (Rickert and Paulus, 2001) . As a function of their location and embryonic origin, MB tend to disseminate towards the subarachnoid space, giving rise to metastases by dissemination through the cerebrospinal fluid (Rickert and Paulus, 2001) .
Histologically, MB can be divided into three subgroups: the classical histological type comprises 70% of all MB; the anaplastic or large cell MB are those of the worst prognosis and lowest frequency (less than 5% of cases); and desmoplastic/nodular type of MB, particularly those affecting infants, have the best chance of cure (Crawford et al., 2007) .
Advances in the molecular classification of medulloblastomas
The molecular study of MB has revealed distinct genetic-molecular expression profiles among the different subgroups of the tumor. Current consensus is that there are at least four major molecular subgroups, denoted Wingless (WNT), Sonic Hedgehog (SHH), Group 3, and Group 4. Therefore, from the anatomopathological viewpoint, MB comprises a set of different subgroups that are part of the same neoplasia (Fellay et al., 2011; Northcott et al., 2011; Kool et al., 2012; Gerber et al., 2014) .
The WNT subgroup, corresponding to 10% of all MB, has a major role in the somatic mutation of the CTNNB1 gene, which codes for the beta-catenin protein. When this protein is not degraded, it accumulates in the cytoplasm, stabilizes, and is then translocated to the nucleus. The accumulation of nuclear beta-catenin leads to the regulation of transcription of a series of target genes mainly involved in cell proliferation. This group may also show germinal mutations in the tumor suppressor APC, as well as in chromosome 6 (monosomy). It usually affects older children with the classical histological subtype of MB, with metastases seldom being present at diagnosis. Moreover, MB with mutations in APC are associated with Turcot syndrome (de Bont et al., 2008; Fellay et al., 2011; Gerber et al., 2014) .
In most cases, the SHH subgroup shows somatic mutations in one or more genes of the SHH pathway (e.g., PTCH1, SUFU, or SMO), which contribute to its constitutive activation. Its histological subtype may be desmoplastic, extensively nodular or classic, and rarely, anaplastic. Its incidence is biphasic, with infants/preschoolers and young adults being affected. The prognosis for infants is excellent when the tumor histology is extensively nodular or desmoplastic. The current tendency in the treatment of this group in infants is to reduce the intensity of therapy in order to increase the likelihood of a cure and to lower the rate of morbidity. Additionally, the MB of the SHH group may be associated with Gorlin syndrome (de Bont et al., 2008; Fellay et al., 2011; Gerber et al., 2014) . Subgroup 3 is almost totally diagnosed in children and very rarely in adults or adolescents. It shows a greater predisposition for males and greater occurrence of metastases at diagnosis. The prognosis for this group is reserved, with the tumor usually belonging to the large cell/anaplastic or classic histological subtypes. MYC is amplified in most cases. In the future, the genes involved in this pathway, as is the case for MYC and others, might become candidates for pharmacological target therapy (de Bont et al., 2008; Fellay et al., 2011; Gerber et al., 2014) .
Subgroup 4 is the most common subgroup, occurs at all ages, can be metastatic at diagnosis, and its prognosis is intermediate. As is the case for group 3, there is no exact description of genetic predisposition. Although in most cases isochromosome 17 is a cytogenetic marker of this subgroup, this is still a poorly characterized group from a molecular viewpoint compared to all the other MB subgroups (de Bont et al., 2008; Fellay et al., 2011; Gerber et al., 2014) .
Analysis of the overall survival of patients with these MB subgroups showed that survival of up to 5 years has been observed in up to 90% of children with the WNT subgroup, as opposed to that observed in 39-58% of children with the 3 and 4 subgroups. This rate of survival depends on the age at tumor occurrence, presence of metastases, and unfavorable coexisting cytogenetic changes. Patients with the SHH subgroup of MB have an intermediate survival rate, while it is particularly longer among infants with the SHH subgroup. This finding is probably associated with the high frequency of desmoplastic histology among SHH tumors in infants since desmoplastic/nodular histology is an isolated marker of favorable prognosis in this age group (Northcott et al., 2011; Fellay et al., 2011; Kool et al., 2012) . Conversely, patients with the SHH subgroup who do not present desmoplastic/nodular histology have a poorer survival rate. This subgroup of MB patients, along with group 3 patients, require new therapeutic approaches that could improve their chance at a cure and reduce the side effects caused by current treatment methods (Northcott et al., 2011; Fellay et al., 2011; Kool et al., 2012) .
Hedgehog signaling pathway
Activation of the SHH signaling pathway is essential during embryonic development for the formation of different tissues and organs. Following this period, the pathway contributes to homeostasis and repair of adult tissues by maintaining stem and progenitor cells and control of cell proliferation and fate. However, when this pathway is activated aberrantly, it could lead to tumor development in different organs (De Smaele et al., 2008) . MB represents one of the different types of tumors that may originate from SHH pathway deregulation (Fellay et al., 2011) . This pathway is responsible for the proliferation of cerebellar cells during development, and the maintenance of its activation after the embryonic period may give rise to MB (Fellay et al., 2011; Gerber et al., 2014) .
The SHH pathway may be activated through signaling by specific ligands and by mutation of the pathway components. The three main ligands that are classified as morphogenic are Sonic hedgehog (SHH), Desert hedgehog (DHH), and Indian hedgehog (IHH); the first being the one most extensively studied (Buczkowicz et al., 2011) .
SHH protein has an initial molecular weight of 45 kDa and autocatalytic activity and may be cleaved into two portions, N-terminal and C-terminal (20 kDa and 25 kDa, respectively) (Shahi et al., 2012) . The carboxyl group at the N-terminal of SHH undergoes a change, forming cholesterol that facilitates its binding, secretion, and transit activities. Involvement of the Dispatched protein is necessary for the paracrine action of SHH. When SHH binds to the patched 1 (PTCH1) transmembrane receptor, smoothened (SMO) (a receptor usually inhibited by PTCH1) is released, undergoes a conformational change, and translocates to the cytoplasm. SMO binds to suppressor of fused homolog (SUFU) in the cytoplasm, consequently releasing proteins belonging to the GLI family. These proteins, GLI1 (activator), GLI 2 (activator), and GLI 3 (inhibitor), translocate to the nucleus, where they act as transcription factors that regulate the expression of different targets such as GLI1, PTCH1, CYCLINE D, and MYC involved in cell survival, proliferation, and differentiation ( Figure 1) (Buczkowicz et al., 2011) . Another mechanism leading to the activation of the SHH pathway is the mutation of inhibitory regulatory genes. An example of this mechanism is somatic mutation and loss of heterozygosity in the gene that codes for the PTCH1 homologue (Robinson et al., 2015) . As is the case for the other components of the SHH signaling pathway, the PTCH1 mutation seems to be sufficient for the development of MB. PTCH mutations have been reported in a subset of pediatric MB (Raffel et al., 1997) , with the observed mutations affecting both the germinal and somatic cell lines, particularly in SUFU (Taylor et al., 2002) . The downstream activity of the GLI protein family is intimately linked to tumorigenesis. The inactivation of both GLI alleles has been reported to lead to MB formation in mice heterozygous for PTCH, suggesting that SHH signaling may direct tumorigenesis in an independent manner (Raffel et al., 1997) .
Even though similar mutation levels are observed in the four groups under study, the genetic sequencing of MB suggests that the different disease types affect individuals belonging to different age brackets (Fellay et al., 2011; Gerber et al., 2014) . SUFU and SMO mutations have most frequently been detected in infants and adults, respectively. TP53 mutations have been detected in almost 50% of patients aged 4-17 years. These results suggest that the treatment of MB can be better directed by considering the patient age range and genetic alteration present (Taylor et al., 2002; Kool et al., 2012) .
Arsenic trioxide (ATO)
The therapeutic application of arsenic has a prodigious history. Knowledge of its medicinal benefits dates back to 400 B.C., with reports on its use by Hippocrates, Aristoteles, Dioscorides, and Pliny (Au, 2011) .
ATO is a known drug that has been studied and used to treat different diseases. Its carcinogenic action is believed to have been observed first in Paris (1822), where cattle grazing in the proximity of foundries developed neoplasias in their flanks. The onset of these tumors was attributed to gases impregnated with large amounts of these substances emitted by the foundries. In 1888, Hutchinson reported six cases of skin cancer in patients who had ingested arsenic for the treatment of dermatoses, to the London Pathology Society (Au, 2011) . Interestingly, ATO was also used on battlefields in World War II in the form of a lethal gas called Lewisite in honor of the American chemist W. Lee Lewis (Au, 2011) .
After decades of minimal use, it is interesting to note that ATO emerged again in the 21st century as one of the drugs used for the treatment of acute promyelocytic leukemia M3, refractory to first line treatment, with promising results (Nasr et al., 2008) .
ATO is a metal element known to exert its biological effect by direct interaction of its trivalent anion AsO 3 -and the thiol groups of cysteines in the proximity of target proteins (Nasr et al., 2008) (Figure 2 ). In the Zn-finger protein involved in acute promyelocytic anemia (PML), the N-terminal domain is rich in cysteine and includes a principal ring (R) and a helix domain (Lu et al., 2007) .
In a study of patients with PML with CNS relapse or under intrathecal prophylaxis, Au (2011) demonstrated that enterally administered arsenic reached a satisfactory concentration in the CNS. The author also demonstrated a correlation between serum and cerebrospinal fluid levels of ATO, with the CNS concentration being 17.7% of the plasma level.
ATO has been approved by the food and drug administration for the treatment of PML. This drug shows good permeability in the CNS and is implicated in the inhibition of a central pathway of genes activated in MB. Overall, all of these characteristics cause ATO to be a considerably attractive drug for the study of its therapeutic potential against MB of the SHH subgroup in vitro and in animal models (Nakamura et al., 2013) .
MATERIAL AND METHODS
This is an integrative literature review and conducted in order to answer the following guiding question: Which inhibitory mechanism of subgroup 2 of medulloblastoma (SHH) involves the Gli gene? To this end, a bibliographic study was performed using four databases: PUBMED (United States National Library of Medicine), BVS (Biblioteca Virtual em Saúde), WEB OF SCIENCE (Institute for Scientific Information-ISI), and EMBASE (Excerpta Medica Database). The investigation was carried out in March 2016 based on a time cut-off of 10 years for the inclusion of articles.
The controlled key words were used for the search were "medulloblastoma", "sonic hedgehog protein", and "regulatory mechanism" and the consequent uncontrolled key words are listed in Table 1 . There was wide variation in the different databases, mainly regarding the uncontrolled key words, as shown in Table 1 . The Boolean operator AND was used among the controlled key words, and OR was used among the uncontrolled key words.
The following criteria were used for the inclusion of articles in the study: primary full papers dealing with inhibitory mechanisms of the SHH pathway of MB subgroup 2 involving Gli1; and papers published in Portuguese, English, and Spanish. Article exclusion criteria: letters, editorials, case reports, pilot studies, and papers whose subjects dealt with inhibition of other subgroups. The endNote X7 software (Thomson Reuters) was used as an instrument aiding the search of papers and references. 
RESULTS
A total of 634 records were detected in the different databases used. Thirty-seven records were first excluded owing to duplication, and the exclusion of 551 publications was based on criteria described at Material and Methods section. Therefore, 46 full papers were selected. Of these, 40 were assessed for eligibility, with a final exclusion of 6 papers since they did not contain answers to the guiding question. The PRISMA diagram (Figure 3 ) details the methodology for the selection of articles for the review, (Table 2 ). Curcumin reduced beta-catenin levels and activated the phosphorylated form of Akt and NF-kappa B, leading to negative regulation of the three main common effectors, i.e., C-myc, N-myc, and cyclin D1. Consequently, apoptosis was triggered by curcumin through the mitochondrial pathway by the negative regulation of the Bcl-2 protein, an antiapoptotic downstream effector of Shh Functional assays using the drug curcumin Continued on next page Survival rates were better in patients with a strong nuclear reaction for Gli1 than in patients with GLI1-negative medulloblastomas. Immunohistochemical detection of Gli1 may be useful for the identification of medulloblastomas with activation of the SHH pathway. As revealed by nuclear reaction for Gli1, the SHH pathway is activated in about 60% of all medulloblastomas. In some medulloblastomas, both SHH and WNT seem to be activated. PARP1 is highly expressed in medulloblastomas and may be useful as a target for increasing the efficacy of treatment modalities 
DISCUSSION

ATO as a Gli inhibitor
Strategies for the inhibition of SHH pathways are being constantly developed. Initially, the idea was to develop a drug that would function as a central regulator of the SHH pathway by directly acting on the SMO protein. Within this context, cyclopamide was considered. Cyclopamide was first described as a steroidal alkaloid and later found to be an SMO receptor antagonist (Kim et al., 2010) . Several other SMO inhibitors were then developed, four of them, i.e., Vismodegib (GDC-0449), NVP-LDE225 (Novartis), IPI-926 (Infinito), and XL-139 (BMS/ Exelis) progressing to phase II clinical assays. All of these compounds act as competitive inhibitors of the cyclopamide ligand (Kim et al., 2010) . The response to treatment with these drugs was initially positive; however, cases of drug resistance were observed after a certain period of use. Possible causes of this resistance were reported to be Gli 2 changes, cyclin D1 amplification, and PI3K-AkT-mTOR signaling pathway activation (Kim et al., 2010) .
New strategies for the inhibition of the SHH pathway were investigated based on the observation that GLI1 and GLI2 expressions confer a poor prognosis to pediatric MB, with GLI2 playing a central role in SHH activation. GLI2 expression leads to a change in morphology and a reduction in viability, cell numbers, and apoptosis in MB. The GLI1 protein is transcribed together with GLI2 but has no principal action, only representing an activation marker of the pathway, a fact indicating GLI2 as a possible target of therapy (Buczkowicz et al., 2011) .
It had been reported that ATO acts on Ewing sarcoma cell lines and MB because of its interaction with GLI; however, the exact mechanism of action was unknown. Beauchamp et al. (2009) demonstrated that the relevant mechanism included direct intranuclear binding of ATO to DNA, with no change in the intracytoplasmic or nuclear GLI protein concentrations (Beauchamp et al., 2011) .
The effect of ATO on PML has been well established, with the drug being used widely to achieve remission in induction failure (Nasr et al., 2008) . ATO integration with Zn-fingers of the PML protein alters the conformation of the protein and promotes its degradation. Similarly, ATO inhibits tumor growth by inhibiting the ciliary accumulation of Gli 2, promoting its degradation. The combination of itraconazole and ATO for the treatment of MB has been tested in PTCH-positive and TP 53-negative animals, demonstrating synergism with a reduction in tumor volume. ATO in monotherapy or in combination with itraconazole inhibits the SHH pathway by distinct mechanisms (Nasr et al., 2008; Kim et al., 2010) .
It has been demonstrated that ATO inhibits tumor growth by blocking the transcription of GLI pathway components. ATO also reduced the expression of genes of the SHH pathway, such as PTCH1, GLI1, and GLI2 in human osteosarcoma cell lines (Nakamura et al., 2013) . The same study also reported that treatment with ATO promoted apoptosis of neoplastic cells caused by the accumulation of direct DNA damage. Studies of bone tumor cell lines (Ewing sarcoma) also revealed sensitivity to the use of ATO, with direct binding of GLI1 to the EWS-FLI1 oncoprotein (Beauchamp et al., 2011) .
Roboz and his collaborators demonstrated that ATO has the ability to induce apoptosis of leukemia cells and endothelial blood vessel cells in a dose-and time-dependent manner (Roboz et al., 2000) . In this study model, ATO inhibits endothelial cells by vascular endothelial growth factor (VEGFA) inhibition via a vascular receptor, with the consequent suppression of angiogenesis and tumor growth (Ge et al., 2015) . Using the microRNA profile of endothelial cells derived from stem cells, miR-126 has been reported to directly and negatively regulate VEGFA signaling through PI3KR2 and SPRED1, both regulators of this pathway (Ge et al., 2015) . One of the possible study limitations is the retrospective nature of study reviews on the subject. Although we opted to use several databases with ample literature coverage, some inclusive articles may have escaped our search criteria.
CONCLUSIONS
New strategies for the treatment of MB are being explored. The SHH pathway and its components, PTCH1, SMO, and SUFU, were first investigated in an attempt to develop a specific drug for the blockade of these pathways. Initially, clinical results of this intervention were positive; however, drug resistance was observed after a period of therapeutic use. In continued attempts at blockade, the Gli gene has been a little explored target. Drugs that directly block Gli could potentially be included in the standard therapeutic scheme (polychemotherapy and/or radiotherapy). With a singular history, ample clinical use, and good CNS penetration, arsenic trioxide is still being investigated today in a field beyond that of leukemias. Preclinical studies of ATO in brain tumors, in which the participation of the SHH pathway is involved, have demonstrated an acceptable profile for the assessment of this drug in animal models of MB both in combination with chemotherapy and as a radiosensitizing agent.
